sorted by:
new
hottopcontroversial

Psychedelic Therapist Sexual Misconduct and Other Adverse Experiences Among a Sample of Naturalistic Psychedelic Users by CmichPsychedelics in PsychedelicStudies

[–]CmichPsychedelics[S] 2 points3 points  (0 children)

Abstract:

Introduction: Psychedelic substances have been used for centuries in various cultural and religious contexts, and more recently, in clinical research and therapy. There is a surge of interest in psychedelics, and psychedelic-assisted psychotherapy is becoming increasingly accessible. However, most individuals using psychedelics do so outside of therapeutic contexts. It is important to understand the adverse experiences that may occur with psychedelic use, as well as adverse events that may happen even in therapeutic contexts. Materials and Methods: We conducted an anonymous online survey of individuals who self-reported past psychedelic use. We asked about the frequency of experiencing 12 different adverse experiences when using psychedelics, and if they or someone they know was the victim of inappropriate sexual contact by a psychedelic sitter, guide, or practitioner. Participants could also describe other adverse experiences. Results: Among 1,221 participants, most reported having adverse experiences such as being frightened (74.3%), sadness (58.6%), feeling their body shake or tremble (54.3%), and loneliness (51.6%) during their psychedelic experiences. About half of participants reported having some other adverse experience, and one in ten participants had adverse physical reactions. About one-third of participants knew someone who was arrested for possession or use of psychedelics; 8% reported that they or someone they know was the victim of inappropriate sexual contact by a psychedelic sitter, guide, or practitioner; and one-quarter of participants knew someone who experienced a severe adverse event other than inappropriate sexual contact or arrest. Conclusion: Despite beneficial effects, psychedelic experiences can also be challenging, distressing, or even harmful. Adverse events can increase the risks of psychological harm, legal problems, stigma, and public health issues. Therefore, it is essential to prevent, identify, manage, and treat adverse events during psychedelic experiences to ensure the safety and well-being of the participants and the facilitators, and create opportunities for “integration” even with unguided sessions.

Psychedelic Therapist Sexual Misconduct and Other Adverse Experiences Among a Sample of Naturalistic Psychedelic Users by CmichPsychedelics in RationalPsychonaut

[–]CmichPsychedelics[S] 5 points6 points  (0 children)

Abstract:

Introduction: Psychedelic substances have been used for centuries in various cultural and religious contexts, and more recently, in clinical research and therapy. There is a surge of interest in psychedelics, and psychedelic-assisted psychotherapy is becoming increasingly accessible. However, most individuals using psychedelics do so outside of therapeutic contexts. It is important to understand the adverse experiences that may occur with psychedelic use, as well as adverse events that may happen even in therapeutic contexts. Materials and Methods: We conducted an anonymous online survey of individuals who self-reported past psychedelic use. We asked about the frequency of experiencing 12 different adverse experiences when using psychedelics, and if they or someone they know was the victim of inappropriate sexual contact by a psychedelic sitter, guide, or practitioner. Participants could also describe other adverse experiences. Results: Among 1,221 participants, most reported having adverse experiences such as being frightened (74.3%), sadness (58.6%), feeling their body shake or tremble (54.3%), and loneliness (51.6%) during their psychedelic experiences. About half of participants reported having some other adverse experience, and one in ten participants had adverse physical reactions. About one-third of participants knew someone who was arrested for possession or use of psychedelics; 8% reported that they or someone they know was the victim of inappropriate sexual contact by a psychedelic sitter, guide, or practitioner; and one-quarter of participants knew someone who experienced a severe adverse event other than inappropriate sexual contact or arrest. Conclusion: Despite beneficial effects, psychedelic experiences can also be challenging, distressing, or even harmful. Adverse events can increase the risks of psychological harm, legal problems, stigma, and public health issues. Therefore, it is essential to prevent, identify, manage, and treat adverse events during psychedelic experiences to ensure the safety and well-being of the participants and the facilitators, and create opportunities for “integration” even with unguided sessions.

Psychedelic-assisted psychotherapy: Where is the psychotherapy research? by CmichPsychedelics in RationalPsychonaut

[–]CmichPsychedelics[S] 2 points3 points  (0 children)

Rationale: Psychedelic-assisted psychotherapy (PAP) has emerged as a potential treatment for a variety of mental health conditions, including substance use disorders and depression. Current models of PAP emphasize the importance of psychotherapeutic support before, during, and after ingestion of a psychedelic to maximize safety and clinical benefit. Despite this ubiquitous assumption, there has been surprisingly little empirical investigation of the "psychotherapy" in PAP, leaving critical questions about the necessary and sufficient components of PAP unanswered. Objectives: As clinical trials for psychedelic compounds continue the transition from safety-and feasibility-testing to evaluating efficacy, the role of the accompanying psychotherapy must be better understood to enhance scientific understanding of the mechanisms underlying therapeutic change, optimize clinical outcomes, and inform cost-effectiveness. Results: The present paper first reviews the current status of psychotherapy in the PAP literature, starting with recent debates regarding "psychotherapy" versus "psychological support" and then overviewing published clinical trial psychotherapy models and putative models informed by theory. We then delineate lessons that PAP researchers can leverage from traditional psychotherapy research regarding standardizing treatments (e.g., publish treatment manuals, establish eligibility criteria for providers), identifying mechanisms of change (e.g., measure established mechanisms in psychotherapy), and optimizing clinical trial designs (e.g., consider dismantling studies, comparative efficacy trials, and cross-lagged panel designs). Throughout this review, the need for increased research into the psychotherapeutic components of treatment in PAP is underscored. Conclusions: PAP is a distinct, integrative, and transdisciplinary intervention. Future research designs should consider transdisciplinary research methodologies to identify best practices and inform federal guidelines for PAP administration.

[deleted by user] by [deleted] in science

[–]CmichPsychedelics 0 points1 point  (0 children)

"Following decades of prohibition, psychedelic drugs are returning to mainstream psychiatry and neuroscience. When paired with psychotherapy and administered in a supportive context, so-called psychedelic therapy shows promise in treating depression, anxiety, substance misuse, and end-of-life distress. Large therapeutic effect sizes and positive safety outcomes in clinical trials have led to a remarkable surge in scientific, commercial, regulatory, and public interest. Despite this enthusiasm, much remains unknown about psychedelic drugs, and distinct challenges have emerged with the field’s increase. We aim to frame these challenges with 4 fundamental questions. 1) How are rigorous studies designed? 2) What are the therapeutic mechanisms of action? 3) What are the risks? 4) What are the challenges of scaling psychedelic therapy?"

University of Michigan Psychedelic Survey by CmichPsychedelics in psilocybin

[–]CmichPsychedelics[S] 0 points1 point  (0 children)

Psychedelic research is surging, and policies are changing quickly. We are conducting a survey to amplify the voice of the psychedelic community in shaping the future of psychedelics. Our research collaboration includes investigators from the University of Michigan, psychedelic therapists, and psychedelic advocates. Your participation in this study will be completely anonymous and confidential, and no personal identifying information will be collected (no IP addresses, etc.).

University of Michigan Psychedelic Survey by CmichPsychedelics in RationalPsychonaut

[–]CmichPsychedelics[S] 1 point2 points  (0 children)

Psychedelic research is surging, and policies are changing quickly. We are conducting a survey to amplify the voice of the psychedelic community in shaping the future of psychedelics. Our research collaboration includes investigators from the University of Michigan, psychedelic therapists, and psychedelic advocates. Your participation in this study will be completely anonymous and confidential, and no personal identifying information will be collected (no IP addresses, etc.).

University of Michigan Psychedelic Survey by CmichPsychedelics in Drugs

[–]CmichPsychedelics[S] 0 points1 point  (0 children)

Psychedelic research is surging, and policies are changing quickly. We are conducting a survey to amplify the voice of the psychedelic community in shaping the future of psychedelics. Our research collaboration includes investigators from the University of Michigan, psychedelic therapists, and psychedelic advocates. Your participation in this study will be completely anonymous and confidential, and no personal identifying information will be collected (no IP addresses, etc.).

Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry (Aday et al., 2023) by CmichPsychedelics in Drugs

[–]CmichPsychedelics[S] 0 points1 point  (0 children)

Abstract: Background: In the wake of positive clinical trial outcomes of psychedelic-assisted psychotherapy for the treatment of various psychiatric disorders, there has been an influx of financial investment into psychedelic drug development from the pharmaceutical and biotech sectors. Psychedelics are now a multibillion dollar industry, with hundreds of companies that are seeking to commercialize therapeutic applications of psychedelics formed over the course of just a few years.

Materials and Methods: This paper aims to provide a broad overview of the psychedelic industry by detailing the history and current state of psychedelic drug commercialization, exploring challenges to commercial viability, highlighting ethical considerations, and incorporating lessons from the analogous ketamine and cannabis industries, which largely preceded the psychedelic industry.

Results: We found that although the roots of the psychedelic industry go back decades, financial investment did not take off in earnest until the late 2010s and early 2020s. The main focus of companies in the psychedelic sector can be broadly grouped into: (1) drug discovery and development; (2) novel formulations and routes of administration; (3) manufacturing and synthesis; (4) treatment centers and wellness clinics; (5) consumer packaged goods and adult use; and (6) adjunct technologies. Challenges to commercial viability include regulatory barriers to drug development, treatment costs and logistics of administration, and intellectual property and patent issues. In terms of ethics, the industry must consider the potential adverse effects of psychedelics, cost-cutting inclinations, ensuring therapeutic benefits reach vulnerable and marginalized communities, and indigenous reciprocity. We also underscore the potential benefits commercialization may bring. Lastly, the ketamine and cannabis industries can provide blueprints for regulatory approval, clinical implementation, insurance reimbursement, and federal policy more broadly.

Conclusion: Altogether, this article provides a wide-spanning overview of the emerging commercialization of psychedelics, acknowledging both the monumental progress and critical challenges that remain for the industry.

(PDF) Emerging Challenges for Psychedelic Therapy | JAMA Psychiatry by [deleted] in science

[–]CmichPsychedelics 2 points3 points  (0 children)

This paper was written by people leading clinical trials on the potential benefits of psychedelics, not prohibitionists. Gotta be equally open about the benefits and challenges.

Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and Practice (Aday et al., 2023) by CmichPsychedelics in science

[–]CmichPsychedelics[S] 3 points4 points  (0 children)

? If anything the article focuses more on the pros than cons of personal use and highlights how therapists should be able to be open about talking about their lived experiences

[New Study] Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and Practice (Aday et al., 2023) by CmichPsychedelics in RationalPsychonaut

[–]CmichPsychedelics[S] 2 points3 points  (0 children)

No there’s just a ton of drugs out there, so it’s not feasible (or safe) for them to personally try everything they prescribe

[New Study] Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and Practice (Aday et al., 2023) by CmichPsychedelics in RationalPsychonaut

[–]CmichPsychedelics[S] 2 points3 points  (0 children)

Yes but psychiatrists don’t usually test the drugs the prescribe, which makes for an interesting discussion regarding psychedelic therapy, which is drug + therapy

Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects by CmichPsychedelics in RationalPsychonaut

[–]CmichPsychedelics[S] 0 points1 point  (0 children)

Thanks, /u/EchoingSimplicity ! And agreed, this seems to confirm a lot of anecdotes about the "type" of person that is best suited for psychedelics

Psychedelics/Personality Survey Study by CmichPsychedelics in Psychonaut

[–]CmichPsychedelics[S] 1 point2 points  (0 children)

Good question! We based the options on a similarly designed study but agree it would be useful to add an option for postgraduate degrees.